Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blinded, Multi-Center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidaxole 500mg Every 12h for the Treatment of Patients With Complicated Intra-Abdominal Infections.

Trial Profile

A Prospective, Randomized, Double-Blinded, Multi-Center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidaxole 500mg Every 12h for the Treatment of Patients With Complicated Intra-Abdominal Infections.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Moxifloxacin (Primary) ; Ceftriaxone; Metronidazole
  • Indications Bacteroides infections; Escherichia coli infections; Intra-abdominal infections
  • Focus Therapeutic Use
  • Acronyms DRAGON
  • Sponsors Bayer
  • Most Recent Events

    • 01 Nov 2009 Primary endpoint 'Clinical success rate' has been met.
    • 01 Nov 2009 Results published in the International Journal of Antimicrobial Agents.
    • 23 Oct 2008 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top